[
  {
    "ts": null,
    "headline": "MAVIRET® receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus",
    "summary": "AbbVie (NYSE: ABBV) announced today that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir tablets) for the treatment of acute and chronic hepatitis C virus (HCV) infection in adults and pediatric patients 3 years of age and older and weighing ≥ 12 kg.2 It is the first and only oral eight-week pan-genotypic treatment option approved in Canada.",
    "url": "https://finnhub.io/api/news?id=abd7c70d5d981f3d786384de348afeaebae195f52a812e68230936f285bdf8d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767700860,
      "headline": "MAVIRET® receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus",
      "id": 137999371,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) announced today that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir tablets) for the treatment of acute and chronic hepatitis C virus (HCV) infection in adults and pediatric patients 3 years of age and older and weighing ≥ 12 kg.2 It is the first and only oral eight-week pan-genotypic treatment option approved in Canada.",
      "url": "https://finnhub.io/api/news?id=abd7c70d5d981f3d786384de348afeaebae195f52a812e68230936f285bdf8d4"
    }
  }
]